Humans ; Influenza A Virus, H5N1 Subtype ; Influenza A Virus, H7N9 Subtype ; Influenza, Human ; drug therapy

Antiviral Agents ; therapeutic use ; Humans ; Influenza A Virus, H7N9 Subtype ; pathogenicity ; Influenza, Human ; drug therapy ; epidemiology ; virology

OBJECTIVETo describe the clinical manifestations and lung imaging characteristics of the human transmissible highly pathogenic H5N1 avian influenza.

METHODSThe clinical manifestations and lung imaging characteristics of human transmissible highly pathogenic H5N1 avian influenza in one patient were reviewed and analyzed.

RESULTSThe patient had the clear history of occupational exposure. The fever and symptoms of influenza were prominent at onset and associated with the symptoms of the digestive tract. The laboratory findings comprised the significant decrease of the white blood cell count and the lymphocyte number and the impairment of the liver function and the myocardial enzymes. The disease progressed rapidly and multiple organs including lung, heart, liver and kidneys were involved. It was ineffective to administer anti-fungal, anti-virus and anti-inflammation medicines. It was in vain to use mechanical ventilation and pneumothorax intubation and closed drainage as well as the support therapy. In the X-ray film, the lesions progressed quickly and changed diversely with absorption and development at the same time. The nasal and throat swabs and the gargle specimen were detected with RT-PCR and real time PCR by Chinese Center for Disease Control and Prevention. The results showed that both the specific HA and NA genes of the avian influenza virus H5N1 subtype were positive and in the same time a strain of avian influenza virus A/jiangxi/1/2005H5N1) was separated and obtained from the nasal and throat swabs. The autopsy showed that diffuse injury of alveolus in lungs, DIC and multiple organ injury.

CONCLUSIONThe human transmissible highly pathogenic H5N1 avian influenza is a lethal disease. The disease progresses rapidly with the absorption and development at the same time in the lungs and unfortunately there are no effective therapeutic measures. The prevention of the contagious disease for the occupationally exposed population should be emphasized.

Adult ; Humans ; Influenza A Virus, H5N1 Subtype ; Influenza, Human ; diagnosis ; etiology ; therapy ; Male ; Occupational Exposure ; adverse effects

China ; epidemiology ; Humans ; Influenza Vaccines ; Influenza, Human ; epidemiology ; prevention & control ; therapy

Since the first human case of influenza A virus subtype H7N9 was reported in Shanghai, China in March 2013, there have been two H7N9-infected children and one healthy H7N9 carrier. With a brief introduction to the basic information of the three children, this paper discusses the variation of Avian influenza virus by referring to the literature, suggests that human-to-human transmission is not confirmed in the small outbreak, and reviews the measures for preventing and treating H7N9 infection in humans. In addition, this paper talks about the use of tamiflu in early stage of infection and the use of peramivir when the patient's condition is severe.
Animals ; Birds ; Child ; Child, Preschool ; Humans ; Influenza A virus ; genetics ; Influenza in Birds ; virology ; Influenza, Human ; drug therapy ; prevention & control ; transmission

Humans ; Influenza A Virus, H5N1 Subtype ; classification ; genetics ; pathogenicity ; Influenza Vaccines ; immunology ; Influenza, Human ; drug therapy ; prevention & control ; transmission ; Vaccination

Seasonal influenza epidemics and influenza pandemics caused by influenza A virus (IAV) has resulted in millions of deaths in the world. The development of anti-IAV vaccines and therapeutics is urgently needed for prevention and treatment of IAV infection and for controlling future influenza pandemics. Hemagglutinin (HA) of IAV plays a critical role in viral binding, fusion and entry, and contains the major neutralizing epitopes. Therefore, HA is an attractive target for developing anti-IAV drugs and vaccines. Here we have reviewed the recent progress in study of conformational changes of HA during viral fusion process and development of HA-based antiviral therapeutics and vaccines.
Antiviral Agents ; therapeutic use ; Epidemics ; Hemagglutinins ; physiology ; Humans ; Influenza A virus ; immunology ; Influenza Vaccines ; immunology ; Influenza, Human ; immunology ; therapy ; Pandemics

Acinetobacter Infections ; complications ; diagnosis ; therapy ; Acinetobacter baumannii ; Animals ; Birds ; Humans ; Influenza A Virus, H7N9 Subtype ; Influenza, Human ; complications ; diagnosis ; microbiology ; therapy

Antiviral Agents ; therapeutic use ; Humans ; Influenza A Virus, H7N9 Subtype ; pathogenicity ; Influenza, Human ; diagnosis ; diet therapy ; Middle Aged

Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Influenza A Virus, H1N1 Subtype ; Influenza, Human ; diagnosis ; drug therapy ; Male ; Retrospective Studies